\-\ Texto\\:\\ \ \(0\)\
\-\ vitals\\ demonstrates\\ hypertension\\ \\(\\>190\\/\\>110\\)\\ without\\ laboratory\\ evidence\\ of\\ end\\-organ\\ damage\\ \\(i\\.e\\.\\,\\ hypertensive\\ urgency\\)\\.\ \(0\)\
\-\ pe\\ is\\ normal\\ with\\ non\\-focal\\ neurologic\\ exam\\.\ \(0\)\
\-\ bun\\ \\-\\ 17\ \(0\)\
\-\ creatinine\\ \\-\\ 1\\.2\ \(0\)\
\-\ the\\ most\\ significant\\ therapy\\ for\\ those\\ with\\ symptomatic\\ adpkd\\ involves\\ the\\ management\\ of\\ hypertension\\ and\\ associated\\ sequelae\\.\\ screening\\ for\\ mca\\ berry\\ aneurysms\\.\ \(0\)\
\-\ multiple\\,\\ bilateral\\,\\ cystic\\ lesions\\ are\\ present\\ on\\ non\\-contrast\\ mr\\.\\ \\ cysts\\ do\\ not\\ enhance\\ with\\ contrast\\ on\\ mr\\.\\ \\ 3d\\ mra\\ demonstrates\\ the\\ distribution\\ of\\ cysts\\.\\ \\ there\\ are\\ no\\ cystic\\ lesions\\ in\\ the\\ surrounding\\ tissues\\ or\\ organs\\.\ \(0\)\
\-\ autosomal\\ dominant\\ \\"adult\\"\\ polycystic\\ kidney\\ disease\\ \\(adpkd\\)\\.\\ \\ \ \(0\)\
\-\ family\\ hx\\ revealed\\ pt\\'s\\ father\\ with\\ history\\ of\\ htn\\,\\ rf\\,\\ and\\ subarachnoid\\ hemmorhage\\.\ \(0\)\
\-\ 1\\.\\ renal\\ cysts\ \(0\)\
\-\ 2\\.\\ acquired\\ polycystic\\ disease\\ \ \(0\)\
\-\ 3\\.\\ autosomal\\ recessive\\ polycystic\\ kidney\\ disease\\ \ \(0\)\
\-\ 4\\.\\ medullary\\ kidney\\ disorders\\ \ \(0\)\
\-\ \\ \\ \\ \\-medullary\\ sponge\\ kidney\ \(1\)\
\-\ \\ \\ \\ \\-medullary\\ cystic\\ kidney\ \(1\)\
\-\ 41\\ y\\/o\\ black\\ male\\ presented\\ to\\ the\\ er\\ with\\ atypical\\ chest\\ pain\\.\ \(0\)\
\-\ with\\ routine\\ screening\\ of\\ blood\\ pressure\\,\\ hypertension\\ has\\ become\\ the\\ leading\\ initial\\ presenting\\ symptom\\ of\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ polycystic\\:\\ 0\\.10753868741006245\ \(0\)\
\-\ kidney\\:\\ 0\\.096076067714362\ \(0\)\
\-\ autosomal\\:\\ 0\\.07889868212327565\ \(0\)\
\-\ \\-medullary\\:\\ 0\\.07666043097374892\ \(0\)\
\-\ adpkd\\:\\ 0\\.06364154340330087\ \(0\)\
\-\ hypertension\\:\\ 0\\.05375714445159874\ \(0\)\
\-\ cysts\\:\\ 0\\.05341688749198989\ \(0\)\
\-\ 190\\/\\:\\ 0\\.04689105544663031\ \(0\)\
\-\ dominant\\:\\ 0\\.0463954375288616\ \(0\)\
\-\ end\\-organ\\:\\ 0\\.039517149270460676\ \(0\)\
\-\ berry\\:\\ 0\\.039517149270460676\ \(0\)\
\-\ cystic\\:\\ 0\\.0393292453284855\ \(0\)\
\-\ screening\\:\\ 0\\.03877696200987603\ \(0\)\
\-\ hemmorhage\\:\\ 0\\.03583019618237586\ \(0\)\
\-\ 110\\:\\ 0\\.0332477078005583\ \(0\)\
\-\ urgency\\:\\ 0\\.0332477078005583\ \(0\)\
\-\ non\\-focal\\:\\ 0\\.0332477078005583\ \(0\)\
\-\ i\\.e\\.\\:\\ 0\\.03214324309429105\ \(0\)\
\-\ rf\\:\\ 0\\.03182077170165044\ \(0\)\
\-\ sponge\\:\\ 0\\.03182077170165044\ \(0\)\
\-\ 3d\\:\\ 0\\.03122914598297903\ \(0\)\
\-\ recessive\\:\\ 0\\.030212894723602918\ \(0\)\
\-\ \\>\\:\\ 0\\.03020390973051664\ \(0\)\
\-\ disease\\:\\ 0\\.029717820025866044\ \(0\)\
\-\ mr\\:\\ 0\\.028885100765387597\ \(0\)\
\-\ 1\\.2\\:\\ 0\\.02862516606107102\ \(0\)\
\-\ aneurysms\\:\\ 0\\.027269356222620007\ \(0\)\
\-\ father\\:\\ 0\\.027138012538628672\ \(0\)\
\-\ sequelae\\:\\ 0\\.027009834072782603\ \(0\)\
\-\ hypertensive\\:\\ 0\\.026884671852515613\ \(0\)\
\-\ mca\\:\\ 0\\.026411546926895957\ \(0\)\
\-\ black\\:\\ 0\\.02618988364816953\ \(0\)\
\-\ organs\\:\\ 0\\.026082422439033786\ \(0\)\
\-\ creatinine\\:\\ 0\\.02587380162438867\ \(0\)\
\-\ symptom\\:\\ 0\\.025772481438374344\ \(0\)\
\-\ mra\\:\\ 0\\.025479610283145472\ \(0\)\
\-\ bun\\:\\ 0\\.025112626924172328\ \(0\)\
\-\ htn\\:\\ 0\\.02502470510528291\ \(0\)\
\-\ acquired\\:\\ 0\\.024369212337070418\ \(0\)\
\-\ lesions\\:\\ 0\\.024335750067488806\ \(0\)\
\-\ damage\\:\\ 0\\.02429267649955925\ \(0\)\
\-\ 41\\:\\ 0\\.024217226313431824\ \(0\)\
\-\ adult\\:\\ 0\\.02278148367453852\ \(0\)\
\-\ hx\\:\\ 0\\.022502930560084712\ \(0\)\
\-\ non\\-contrast\\:\\ 0\\.02218684853630386\ \(0\)\
\-\ 17\\:\\ 0\\.02213594720111157\ \(0\)\
\-\ subarachnoid\\:\\ 0\\.022085528350289527\ \(0\)\
\-\ enhance\\:\\ 0\\.021986102110863184\ \(0\)\
\-\ medullary\\:\\ 0\\.021840362886458322\ \(0\)\
\-\ vitals\\:\\ 0\\.02174537555986254\ \(0\)\
\-\ disorders\\:\\ 0\\.02174537555986254\ \(0\)\
\-\ leading\\:\\ 0\\.02174537555986254\ \(0\)\
\-\ become\\:\\ 0\\.021652054763847062\ \(0\)\
\-\ involves\\:\\ 0\\.02112410285908461\ \(0\)\
\-\ those\\:\\ 0\\.020682259248985604\ \(0\)\
\-\ distribution\\:\\ 0\\.02045587832122605\ \(0\)\
\-\ pe\\:\\ 0\\.020419067455031508\ \(0\)\
\-\ demonstrates\\:\\ 0\\.019857672358012616\ \(0\)\
\-\ do\\:\\ 0\\.019731771010988924\ \(0\)\
\-\ atypical\\:\\ 0\\.019699631040478484\ \(0\)\
\-\ \\-\\:\\ 0\\.01948647296498259\ \(0\)\
\-\ neurologic\\:\\ 0\\.018981352935138363\ \(0\)\
\-\ tissues\\:\\ 0\\.018655588971091985\ \(0\)\
\-\ family\\:\\ 0\\.018629321515556973\ \(0\)\
\-\ presenting\\:\\ 0\\.01852552995053792\ \(0\)\
\-\ routine\\:\\ 0\\.0182257802880319\ \(0\)\
\-\ symptomatic\\:\\ 0\\.018058422471777722\ \(0\)\
\-\ 4\\.\\:\\ 0\\.01789617005532339\ \(0\)\
\-\ pressure\\:\\ 0\\.0178507069671401\ \(0\)\
\-\ er\\:\\ 0\\.017437149770999794\ \(0\)\
\-\ management\\:\\ 0\\.017151762997104476\ \(0\)\
\-\ pt\\:\\ 0\\.016899807205493365\ \(0\)\
\-\ laboratory\\:\\ 0\\.016750487956670564\ \(0\)\
\-\ 3\\.\\:\\ 0\\.015552522405003868\ \(0\)\
\-\ initial\\:\\ 0\\.015061607145102702\ \(0\)\
\-\ surrounding\\:\\ 0\\.014942368427472156\ \(0\)\
\-\ revealed\\:\\ 0\\.014587627073755815\ \(0\)\
\-\ 2\\.\\:\\ 0\\.01445449011595882\ \(0\)\
\-\ 1\\.\\:\\ 0\\.01419781471434894\ \(0\)\
\-\ renal\\:\\ 0\\.01365678483754292\ \(0\)\
\-\ y\\/o\\:\\ 0\\.012588452286274684\ \(0\)\
\-\ blood\\:\\ 0\\.012406441875049464\ \(0\)\
\-\ are\\:\\ 0\\.012392275239676613\ \(0\)\
\-\ presented\\:\\ 0\\.01239020018628941\ \(0\)\
\-\ significant\\:\\ 0\\.012222591229011827\ \(0\)\
\-\ therapy\\:\\ 0\\.012152344660854323\ \(0\)\
\-\ evidence\\:\\ 0\\.01191724778386637\ \(0\)\
\-\ \\(\\:\\ 0\\.011527048823040327\ \(0\)\
\-\ \\)\\:\\ 0\\.011386239767765505\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.01117093105123307\ \(0\)\
\-\ bilateral\\:\\ 0\\.01103094536869385\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.010956114372245973\ \(0\)\
\-\ chest\\:\\ 0\\.010876218085412333\ \(0\)\
\-\ associated\\:\\ 0\\.010725864690998415\ \(0\)\
\-\ without\\:\\ 0\\.010702197693394469\ \(0\)\
\-\ most\\:\\ 0\\.010493803945362106\ \(0\)\
\-\ present\\:\\ 0\\.010266004010274898\ \(0\)\
\-\ contrast\\:\\ 0\\.010174338759616517\ \(0\)\
\-\ \\'s\\:\\ 0\\.010021524565782154\ \(0\)\
\-\ exam\\:\\ 0\\.009985286914625203\ \(0\)\
\-\ multiple\\:\\ 0\\.009573436188719515\ \(0\)\
\-\ \\,\\:\\ 0\\.008639682942041087\ \(0\)\
\-\ has\\:\\ 0\\.00853563814092701\ \(0\)\
\-\ male\\:\\ 0\\.008219178393018474\ \(0\)\
\-\ for\\:\\ 0\\.0077564696664118625\ \(0\)\
\-\ on\\:\\ 0\\.00770096821665349\ \(0\)\
\-\ normal\\:\\ 0\\.0071255981627611755\ \(0\)\
\-\ there\\:\\ 0\\.0067644444492818544\ \(0\)\
\-\ not\\:\\ 0\\.006568184424159231\ \(0\)\
\-\ history\\:\\ 0\\.006277736902697252\ \(0\)\
\-\ pain\\:\\ 0\\.005551107274099652\ \(0\)\
\-\ or\\:\\ 0\\.005327248664700572\ \(0\)\
\-\ no\\:\\ 0\\.00457683058885001\ \(0\)\
\-\ the\\:\\ 0\\.004412211213945504\ \(0\)\
\-\ with\\:\\ 0\\.003734175832656055\ \(0\)\
\-\ of\\:\\ 0\\.003718206408446439\ \(0\)\
\-\ is\\:\\ 0\\.0029909083956634343\ \(0\)\
\-\ to\\:\\ 0\\.0022716388746967355\ \(0\)\
\-\ \\.\\:\\ 0\\.002265927836000826\ \(0\)\
\-\ in\\:\\ 0\\.002241474628405611\ \(0\)\
\-\ and\\:\\ 0\\.0019149894226831749\ \(0\)\
